Safety, Tolerability and Antimalarial Activity of Single Doses of OZ439 and PQP

Model scores of the 29,894 trials active now.

Model score 6% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 6% of the time (340 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2019-04-19. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: typemsdiabetesinsulininterval
  Phrases that lowered it: healthyvolunteerssinglemalevaccine
• Primary purpose: other (lowers risk) · Design
• Sponsor's past termination rate: 11.1% (raises risk) · Sponsor's track record
• Phase: 1 (lowers risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Collaborators: 3 (lowers risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: parallel (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports marked serious: 100% (raises risk) · Drug's FDA history
• Blinding: none (lowers risk) · Design
• Drug's FAERS reports with a death: 0% (lowers risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 7 (lowers risk) · Sponsor's track record
• Number of arms: 7 (lowers risk) · Design
• Sponsor's past trials: 45 (lowers risk) · Sponsor's track record
• Maximum age: 55 (lowers risk) · Who can join
• Disease area, psychiatry: No (lowers risk) · Disease area
• Responsible party: sponsor (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• SJ733 Induced Blood Stage Malaria Challenge Study NCT02867059 · started 2016 · scored riskier than 3% of active trials completed
• Safety, Tolerability and Chemoprotective Activity of P218 in PfSPZ Challenge Model NCT03707041 · started 2018 · scored riskier than 5% of active trials completed
• Effectiveness of OZ439 as a Gametocytocidal and Transmission Blocking Agent NCT02431650 · started 2015 · scored riskier than 4% of active trials completed
• A Study to Characterise the Antimalarial and Transmission Blocking Activity of a Single Dose of DSM265 or OZ439 in Healthy Subjects With Induced Blood Stage Plasmodium Falciparum or Plasmodium Vivax Infection NCT02573857 · started 2015 · scored riskier than 4% of active trials terminated
• Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of Ruxolitinib With Artemether-lumefantrine NCT04456634 · started 2020 · scored riskier than 5% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.